Regulatory Pfizer’s Hympavzi secures FDA expanded indications for haemophilia Pharmaceutical TechnologyPfizer has received approval from the FDA for an expanded indication of Hympavzi for the treatment of haemophilia A or B.HematologyRead full story pharminent June 9, 2026 (Last updated: June 9, 2026) Pharmaceutical Technology Pfizer has received approval from the FDA for an expanded indication of Hympavzi for the treatment of haemophilia A or B. Hematology Read full story Post navigation Previous: J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1BNext: ADA: AZ reveals oral GLP-1 data in obesity, diabetes Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026